Is Keflex (Cephalexin) effective for treating bacterial vaginosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Keflex (Cephalexin) is NOT Effective for Bacterial Vaginosis Treatment

Keflex (cephalexin) is not recommended for bacterial vaginosis treatment as it is not included in any treatment guidelines for BV. According to CDC guidelines, the recommended first-line treatments for bacterial vaginosis are metronidazole and clindamycin 1, 2.

Recommended Treatment Options for Bacterial Vaginosis

First-Line Treatments

  • Metronidazole 500 mg orally twice daily for 7 days (95% cure rate) 2
  • Metronidazole gel 0.75% intravaginally once daily for 5 days (95% cure rate) 2
  • Clindamycin cream 2% intravaginally at bedtime for 7 days 1

Alternative Regimens

  • Metronidazole 2g orally in a single dose (84% cure rate) 1, 2
  • Clindamycin 300 mg orally twice daily for 7 days 1

Why Keflex Is Not Appropriate for BV

Bacterial vaginosis involves a complex shift in vaginal flora with overgrowth of anaerobic bacteria including Gardnerella vaginalis, Prevotella species, and Mobiluncus species. Keflex (cephalexin) is a first-generation cephalosporin that:

  1. Has poor activity against the anaerobic bacteria that cause BV
  2. Is not included in any treatment guidelines for BV 1, 2
  3. Would not address the underlying microbial imbalance characteristic of BV

Diagnostic Considerations

Proper diagnosis of BV is essential before initiating treatment. BV is diagnosed using Amsel's criteria, which requires the presence of at least 3 of 4 criteria:

  • Homogeneous, white discharge adhering to vaginal walls
  • Presence of clue cells on microscopic examination
  • Vaginal fluid pH greater than 4.5
  • Fishy odor of vaginal discharge before or after addition of 10% KOH (whiff test) 2

Treatment Efficacy Considerations

Recent research has demonstrated that:

  • Oral and vaginal metronidazole have similar efficacy (89.9% vs. 92.5% cure rates), but the vaginal route has significantly fewer side effects 3
  • Dequalinium chloride, a broad-spectrum antiseptic, has been shown to be non-inferior to oral metronidazole with better tolerability in a 2024 study 4
  • Treatment failure rates can be as high as 38.7%, requiring repeat treatment 5
  • Recurrence rates can be as high as 50% within one year of treatment 6

Special Considerations

Pregnancy

For pregnant women, the CDC recommends:

  • First trimester: clindamycin cream
  • Second and third trimesters: metronidazole (oral or gel) or clindamycin cream 2

Side Effects and Precautions

  • Patients using metronidazole should avoid alcohol during treatment and for 24 hours afterward 1
  • Clindamycin cream is oil-based and may weaken latex condoms and diaphragms 1
  • Intravaginal metronidazole causes significantly fewer side effects (nausea: 10.2% vs. 30.4%; abdominal pain: 16.8% vs. 31.9%) compared to oral administration 3

Management of Sexual Partners

Routine treatment of sexual partners is not recommended for BV according to CDC guidelines 1, 2. However, consistent condom use may help prevent recurrence 2.

Follow-Up

Follow-up visits are generally unnecessary if symptoms resolve. However, for pregnant women, a follow-up evaluation one month after treatment completion is recommended 1, 2.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Vaginal Odor Evaluation and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Effectiveness of current therapy of bacterial vaginosis.

International journal of adolescent medicine and health, 2002

Research

Characterization and Treatment of Recurrent Bacterial Vaginosis.

Journal of women's health (2002), 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.